Právní předpis byl sestaven k datu 20.12.2013.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. s. a x. 46/2008 Xx. x. x. a xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 97/2012 Sb. x. x. x Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx
Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx xxx 12. listopadu 2012 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Přílohy X - Seznamu xxxxxxxxxx látek a xxxxx - Xxxxxxxxxxx xxxxxxxx Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx1).
S novým xxxxxx Přílohy X xxxxxxxx xxxxxxx Parlament Xxxxx xxxxxxxxx.
Xxxx xxxxx Přílohy X xxxxxxxxx x xxxxxxxx x xxxxxxx x xxxxxxx 34 odst. 3 Xxxxxx xxx 1. ledna 2013 x tímto dnem xxxxxxxxx x platnost x xxx Xxxxxx xxxxxxxxx. Dnem xxxxxx xxxxxx znění Xxxxxxx X x platnost xxxxxxxx xxxxxx znění Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxx xx 1. xxxxx 2012 a xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Anglické xxxxx Xxxxxxx I x xxxx překlad xx českého jazyka xx xxxxxxxxx současně.
1) Mezinárodní xxxxxx xxxxx dopingu xx xxxxxx xxxxxxx xxx 19. října 2005 v Paříži xxxx xxxxxxxxx pod č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.
PŘÍLOHA I
XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2013
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx od 1. xxxxx 2013
Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, S4.4, X4.5 x X6(x) a Xxxxxxxxxx xxxxx X1, X2 x X3.
| &xxxx;
XXXXX X XXXXXX XXXXXXXX XXXXX
(PŘI XXXXXXX X MIMO XXXXXX)
|
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Seznamu x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx stadiu výzkumu xxxx po xxxxxxxx xxxxxxxxxx, syntetické xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
X1. XXXXXXXXXX XXXXX
Anabolické xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):
(a) Xxxxxxxx* AAS, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (estr-4-en-3β,17β-diol); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); kalusteron; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolon; xxxxxxxxxxx; metasteron (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; metribolon (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-dion); xxxxxxxxxx; norethandrolon; norklostebol; xxxxxxxx; xxxxxxxxxx; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, pokud xxxx xxxxxx exogenně:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-hydroxyandrost-5-en-17-one), xxxxxxxxxxx x xxxxxx xxxxxxxxxx a xxxxxxx, xxx ne x xxxxxxxx pouze xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
|
| &xxxx;
5α-xxxxxxxxx-3α,17β-xxxx
|
&xxxx; |
| &xxxx;
5α-xxxxxxxxx-3β,17α-xxxx
|
&xxxx;
xxx-xxxxxxxxxxxxxxxxxx
|
| &xxxx;
5α-xxxxxxxxx-3β,17β-xxxx
|
&xxxx;
xxxxxxxxxxxxxx
|
| &xxxx;
xxxxxxx-4-xx-3α,17α-xxxx
|
&xxxx;
3α-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-4-xx-3α,17β-xxxx
|
&xxxx;
3β-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
7α-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17α-xxxx
|
&xxxx;
7β-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17β-xxxX
|
&xxxx;
7-xxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
19-xxxxxxxxxxxxxx
|
| &xxxx;
4-xxxxxxxxxxxxx (androst-4-en-3β,17β-diol)
|
19-noretiocholanolon
|
2. Xxxxxxx xxxxxxxxxx xxxxx, zahrnující:
Klenbuterol, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, zilpaterol, xxx xx s xxxxxxxx xxxxx na xx.
| &xxxx;
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx vztahuje x xxxxx, xxxxxx xxxx xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " se xxxxxxxx k látce, xxxxxx může tělo xxxxxxxxxx přirozeně.
|
X2. PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX X XXXXXXXX XXXXX
Xxxxxxxxxxx xxxxx x jejich xxxxxxxxxx xxxxxxx jsou xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (např. xxxxxxxxxxxx (EPO), darbepoetin (xXXX), xxxxxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (CG) x Xxxxxxxxxxxx xxxxxx (XX) x mužů;
3. Xxxxxxxxxxxxxx;
4. Růstový xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx podobný xxxxxxx xxxxxx-1 (IGF-1), xxxxxxxxxx růstové faktory (XXX), xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF) a xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX), xxxxxx jako xxxxxxxxx jiné xxxxxxx xxxxxxx xxxxxxxxxxx syntézu xxxx xxxxxxxxx xxxxxxxx xxxxx, šlach x xxxxxx, krevní xxxxxxxx, xxxxxxx energie, regenerativní xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových vláken;
x další látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
S3. XXXX2- AGONISTÉ
Xxxxxxx xxxx-2 agonisté xxxxxx xxxx případných optických xxxxxxx (xxxx. x- x l-), xxxx xxxxxxxx xxxxx salbutamolu (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx xxxxxx x inhalaci v xxxxxxx s xxxxxxxxxxx xxxxxxxx režimem výrobce.
Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx a přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx považována xx xxxxxxxxx xxxxxxxxxxxx použití, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, pokud xxxxxxxxx xxxxxxxxx kontrolovanou farmakokinetickou xxxxxx, že abnormální xxxxxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx inhalační xxxxx nižší než xxxx xxxxxxx xxxxxxx.
X4. HORMONOVÉ A XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, anastrozol, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
2. Selektivní xxxxxxxxxx estrogenových receptorů (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.
3. Ostatní xxxxxxxxxxxxxx xxxxx zahrnující:
Cyklofenil, xxxxxxxxxxx, xxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx:
x) Xxxxxxxx;
x) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Xxxxxxxxxxxx Activated Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX x xxxxxxxxxxx x XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. XXXXX)
S5. DIURETIKA X OSTATNÍ XXXXXXXXX XXXXX
Xxxxxxxxx látky xxxx xxxxxxxx. Zahrnují:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. glycerol, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x další xxxxx s xxxxxxxxx xxxxxxxxxxxx účinky. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx anestézi xxxx xxxxxxxx.
Xxxxxxxxx zahrnují:
Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx a xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, které nejsou xxxxxxxx).
Xxx xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx prahovým limitem (xx. formoterol, xxxxxxxxxx, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx s xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx xx xxxxxxxxxx udělení specifické Xxxxxxxxxxxx výjimky xx xxxx látku navíc x xx, která xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx maskovací xxxxx.
XXXXXXXX XXXXXX
M1. XXXXXXXXXX X KRVÍ X XXXXXXXX KOMPONENTAMI
Zakázané xx xxxxxxxxxxx:
1. Xxxxxx xxxx znovuzavedení xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx krve nebo xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx systému.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx dodávky xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx na xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx xx x xxxxxxxx xxxxx xx xx. Xxxxxxxxxxxx xxxxxxxx xxxxxxxx není.
3. Jakákoliv forma xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx fyzikálními xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxx, nebo xxxxx x xxxxxx, za xxxxxx xxxxxxx integritu x xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx je zakázané. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, ale xx x omezením xxxxx na xx.
2. Xxxxxxxxxx xxxxxx x/xxxx injekce xxxx xxx 50 ml xx 6 hodin xxxx zakázány kromě xxxxxx xxxxxxxxx xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
X3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx ke xxxxxxx sportovního výkonu xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx nukleových xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
| &xxxx;
LÁTKY X METODY XXXXXXXX XXX XXXXXXX
|
Xxxxx xxxxxxxxx S0 xx X5 x X1 až X3 xxxxxxxxx výše xxxx Xxx Xxxxxxx xxxxxxxx x následující xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Všechna xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx optických isomerů (xxxx. d- x x-) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2013*.
Xxxxxxxxxxx xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, benfluorex, xxxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, famprofazon, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, kropropamid, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (d-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Stimulancium, které xxxx xxxxxxxx uvedeno x xxxxx xxxxxxxx, xx Specifickou látkou.
(x) Specifická xxxxxxxxxxx (xxxxxxxx):
Adrenalin**, katin***, xxxxxxx****, xxxxxxxx, etilefrin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, isomethepten, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (dimetylpentylamin), xxxxxxxxx, xxxxxxxxxxx, oktopamin, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, pentetrazol, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, sibutramin, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.
* Následující xxxxx zahrnuté do Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, fenylefrin, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, pipradrol, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxxxx xxxxxx xxxxxxxxxx (např. xxxxx, xxxx xxxxxxxx) xxxx xxxx xxxxxx společně x lokálními xxxxxxxxxx xxxx xxxxxxxx.
*** Xxxxx xx xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx v 1 xx xxxx.
**** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 ml moči.
***** Pseudoefedrin xx xxxxxxx, xxxxx jeho xxxxxxxxxxx x xxxx xx xxxxx než 150 mikrogramů xx xxxxxxxx
X7. NARKOTIKA
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, dextromoramid, xxxxxxxxx(xxxxxx), xxxxxxxx a jeho xxxxxxxx, xxxxxxxxxxx, metadon, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
S8. XXXXXXXXXXX
Xxxxxxxx (např. xxxxx, xxxxxx a xxxxxxxxx) xxxx syntetický xxxxx9-xxxxxxxxxxxxxxxxxxx (THC) x xxxxxxxxxxxxxx (xxxx. "Spice" /XXX018, XXX073/ a XX-210) xxxx zakázané.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx podávané orálně, xxxxxxxx, nitrožilní xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
| &xxxx;
XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX
|
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Při Xxxxxxx v následujících xxxxxxxx. Detekce xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (hematologická xxxxxxx) xx 0.10 g/l.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Lukostřelba (FITA)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Vodní xxxxxxxxxx (XXX)
P2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx určeno, beta-blokátory xxxx zakázány pouze Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (WCBS)
∙ Xxxx (IGF)
∙ Xxxxxxxxxxx (XXXX, IPC) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Lyžování (XXX) - skoky xx lyžích x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx,x xxxxxxxxx X-xxxxx x "xxx xxx"
∙ Xxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxx (XXX)
Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, nadolol, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x omezením xxxxx xx xx.
Xxxxxxxxx
Xxxxxx xxxxxxx č. 98/2013 Sb. x. x. xxxxx xxxxxxxxx xxxx 20.12.2013.
Xxxxxx xxxxxxx x. 98/2013 Xx. m. x. xxx xxxxxx právním xxxxxxxxx č. 47/2014 Sb. m. s. s xxxxxxxxx xx 20.9.2014.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx změna xxxxx xxxxxxxxx právního xxxxxxxx.